Crane damages New York's Brooklyn Bridge while passing under; no major damage sustained

Nearly 1,000 Canadians with multiple myeloma and their caregivers have e-mailed elected officials asking that pricing talks resume for a cutting-edge immunotherapy that Health Canada approved nearly three years ago but which still isn’t available in this country. The letter writers are pleading with the pan-Canadian Pharmaceutical Alliance, the organization that negotiates confidential discounts on drug prices on behalf of provinces and territories, to cut a deal for Carvykti, a bespoke, one-time-only infusion for the aggressive blood cancer.